Back to today’s briefing

Story perspectives

Obicetrapib and Ezetimibe Cut LDL-C by 48.6%!

5/23/2025

28 2

Summary

Story summary

At the European Atherosclerosis Society Congress 2025, groundbreaking clinical trials revealed that the CETP inhibitor obicetrapib, when paired with ezetimibe, dramatically slashed LDL-cholesterol levels in patients battling atherosclerotic cardiovascular disease. The ongoing phase III TANDEM trial, involving 407 participants, showcased an impressive 48.6% reduction in LDL-C without significant side effects.

1 of 1

Story summary

At the European Atherosclerosis Society Congress 2025, groundbreaking clinical trials revealed that the CETP inhibitor obicetrapib, when paired with ezetimibe, dramatically slashed LDL-cholesterol levels in patients battling atherosclerotic cardiovascular disease. The ongoing phase III TANDEM trial, involving 407 participants, showcased an impressive 48.6% reduction in LDL-C without significant side effects.